MENU
WGO
Back to Top
World Gastroenterology Organisation
World Gastroenterology Organisation
Follow
WGO: Facebook WGO: Twitter
Share

Hepatitis B (HBV)

Level: Clinical Trials: 29 Abstracts

Legend: : Key Development,  : Very Important,  : Important, [no star]: Special Mention

   

Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN.
Fontaine H, Kahi S, Chazallon C, Bourgine M, Varaut A, Buffet C, Godon O, Meritet JF, Saïdi Y, Michel ML, Scott-Algara D, Aboulker JP, Pol S; ANRS HB02 study group., Gut. 2015 Jan;64(1):139-47. doi: 10.1136/gutjnl-2013-305707. Epub 2014 Feb 20.
Comments: No prevention of relapse after discontinuation of treatment

   

Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors.
van Bömmel F, Bartens A, Mysickova A, Hofmann J, Krüger DH, Berg T, Edelmann A., Hepatology. 2015 Jan;61(1):66-76. doi: 10.1002/hep.27381. Epub 2014 Nov 25.
Comments: Prediction of HBeAg seroconversion during treatment

   

Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, Wu X, Peng J, Xu B, Lin Y, Cao Y, Li H, Lin S, Liu Q, Lin T., JAMA. 2014 Dec 17;312(23):2521-30. doi: 10.1001/jama.2014.15704.
Comments: A study on the same topic

Entecavir treatment for up to 5 years in patients with hepatitis B eantigen-positive chronic hepatitis B.
Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, Poordad F, HalotaW, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U., Hepatology. 2010 Feb;51(2):422-30.

Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus.
Poynard T, Ngo Y, Marcellin P, Hadziyannis S, Ratziu V, Benhamou Y, Adefovir Dipivoxil 437 and 438 Study Groups, J Viral Hepat. 2009 Mar;16(3):203-13

Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study.
Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, Zhang SL, Qiao FY, Campbell F, Chang CN, Gardner S, Atkins M, J Viral Hepat. 2009 Feb;16(2):94-103

  

Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study).
Brouwer WP, Xie Q, Sonneveld MJ, Zhang N, Zhang Q, Tabak F, Streinu-Cercel A, Wang JY, Idilman R, Reesink HW, Diculescu M, Simon K, Voiculescu M, Akdogan M, Mazur W, Reijnders JG, Verhey E, Hansen BE, Janssen HL; ARES Study Group., Hepatology. 2015 May;61(5):1512-22. doi: 10.1002/hep.27586. Epub 2015 Feb 27.
 

  

Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study.
Seto WK, Hui AJ, Wong VW, Wong GL, Liu KS, Lai CL, Yuen MF, Chan HL., Gut. 2015 Apr;64(4):667-72. doi: 10.1136/gutjnl-2014-307237. Epub 2014 May 15.
 

 

Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas.
Amaddeo G, Cao Q, Ladeiro Y, Imbeaud S, Nault JC, Jaoui D, Gaston Mathe Y, Laurent C, Laurent A, Bioulac-Sage P, Calderaro J, Zucman-Rossi J., Gut. 2015 May;64(5):820-9. doi: 10.1136/gutjnl-2013-306228. Epub 2014 Jun 9.
 

No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus.
Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, Kitrinos K, Svarovskaia ES, Miller MD, Sorbel J, Heathcote J, Marcellin P, Borroto-Esoda K., Hepatology. 2011 Mar;53(3):763-73. doi: 10.1002/hep.24078. Epub 2010 Dec 22.

Tenofovir improves the outcome in patients with spontaneous reactivation ofhepatitis B presenting as acute-on-chronic liver failure.
Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A., Hepatology. 2011 Mar;53(3):774-80. doi: 10.1002/hep.24109. Epub 2011 Feb 3.

Hepatitis E vaccine: not a moment too soon.
Holmberg SD., Lancet. 2010 Sep 11;376(9744):849-51. Epub 2010 Aug 20.

Durability of peginterferon alfa-2b treatment at 5 years in patients withhepatitis B e antigen-positive chronic hepatitis B.
Wong VW, Wong GL, Yan KK, Chim AM, Chan HY, Tse CH, Choi PC, Chan AW, Sung JJ,Chan HL., Hepatology. 2010 Jun;51(6):1945-53.

Loss of HBsAg antigen during treatment with entecavir or lamivudine innucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, Yang J, Brett-Smith H, Tamez R., J Viral Hepat. 2010 Jan;17(1):16-22. Epub 2009 Jul 19.

Efficacy of entecavir in chronic hepatitis B patients with mildly elevatedalanine aminotransferase and biopsy-proven histological damage.
Wu IC, Lai CL, Han SH, Han KH, Gordon SC, Chao YC, Tan CK, Sievert W, TanwandeeT, Xu D, Neo BL, Chang TT., Hepatology. 2010 Apr;51(4):1185-9.

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J, Kreter B, Hindes R, AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group, Hepatology. 2008 Jul;48(1):99-108

A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.
Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, Petcharapirat P, Marks P, Sasadeusz J, Cooper DA, Bowden S, Locarnini S, Ruxrungtham K, Dore GJ, Hepatology. 2008 Oct;48(4):1062-9

Early on-treatment prediction of response to peginterferon alfa-2a forHBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K,Akarca US, Flisiak R, Verhey E, Van Vuuren AJ, Boucher CA, ter Borg MJ, JanssenHL., Hepatology. 2010 Aug;52(2):454-61.

Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal lowdoses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial.
Launay O, van der Vliet D, Rosenberg AR, Michel ML, Piroth L, Rey D, Colin deVerdière N, Slama L, Martin K, Lortholary O, Carrat F; ANRS HB03 VIHVAC-B Trial., JAMA. 2011 Apr 13;305(14):1432-40.

Peginterferon therapy for HBeAg-negative chronic hepatitis B: less than meets theeye.
Dienstag JL., Am J Gastroenterol. 2010 Aug;105(8):1770-2.

Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: alarge-scale, randomised, double-blind placebo-controlled, phase 3 trial.
Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Wang H, Yang CL, Jiang HM, Cai JP, Wang YJ, Ai X, Hu YM, Tang Q, Yao X, Yan Q, Xian YL, Wu T, Li YM, Miao J,Ng MH, Shih JW, Xia NS., Lancet. 2010 Sep 11;376(9744):895-902. Epub 2010 Aug 20.

Comparative immunogenicity of two vaccination schedules of a combined hepatitis Aand B vaccine in healthy volunteers.
De Schryver A, Verstrepen K, Vandersmissen L, Vandermeeren N, Vernaillen I,Vranckx R, Van Damme P, van Sprundel M., J Viral Hepat. 2010 Aug 24. [Epub ahead of print]

Prediction of sustained response to peginterferon alfa-2b for hepatitis B eantigen-positive chronic hepatitis B using on-treatment hepatitis B surfaceantigen decline.
Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL., Hepatology. 2010 Oct;52(4):1251-7.

Antiviral activity and safety of LB80380 in hepatitis B e antigen-positivechronic hepatitis B patients with lamivudine-resistant disease.
Yuen MF, Han KH, Um SH, Yoon SK, Kim HR, Kim J, Kim CR, Lai CL., Hepatology. 2010 Mar;51(3):767-76.

A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis.
Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E, Hepatology. 2008 Nov;48(5):1460-6

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S, Borroto-Esoda K, Frederick D, Rousseau F, Hepatology. 2008 Sep;48(3):750-8

Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis.
Schiff E, Simsek H, Lee WM, Chao YC, Sette H Jr, Janssen HL, Han SH, Goodman Z, Yang J, Brett-Smith H, Tamez R, Am J Gastroenterol. 2008 Nov;103(11):2776-83

 

A randomized trial of peginterferon alpha-2a with or without ribavirin forHBeAg-negative chronic hepatitis B.
Rijckborst V, ter Borg MJ, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K,Raptopoulou-Gigi M, Ormeci N, Zondervan PE, Verhey E, van Vuuren AJ, Hansen BE,Janssen HL; PARC Study Group., Am J Gastroenterol. 2010 Aug;105(8):1762-9. Epub 2010 May 11.

 

Neglected hepatitis E and typhoid vaccines.
Basnyat B., Lancet. 2010 Sep 11;376(9744):869.